Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.59 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576429 | 0.94 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL4590781 | 0.94 | TLR7 (0.51) | TLR7TLR8NUDT1 | |
| SCHEMBL4576998 | 0.90 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL14025008 | 0.88 | TLR7 (0.59) | TLR7 | |
| SCHEMBL4577363 | 0.88 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL4576981 | 0.87 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL4577917 | 0.87 | TLR7 (0.66) | TLR7TLR8NUDT1 | |
| SCHEMBL4577424 | 0.85 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL4576947 | 0.84 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL4577848 | 0.84 | TLR7 (0.59) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | claimed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | claimed |
| EP-1891008-A1 | OXINDOLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006131186-A1 | OXINDOLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-12-14 | — | — | WO | claimed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TLR7 612/4885TLR8 1652/4885NUDT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.